{
    "clinical_study": {
        "@rank": "70648", 
        "arm_group": [
            {
                "arm_group_label": "Topiramate", 
                "description": "Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with topiramate as mono or add-on therapy with conventional drugs."
            }, 
            {
                "arm_group_label": "Levetiracetam", 
                "description": "Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with levetiracetam as mono or add-on therapy with conventional drugs."
            }, 
            {
                "arm_group_label": "Oxcarbazepine", 
                "description": "Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with oxcarbazepine as mono or add-on therapy with conventional drugs."
            }
        ], 
        "brief_summary": {
            "textblock": "The Objective of this study is to compare 2-year retention rate of topiramate, levetiracetam\n      and oxcarbazepine in a long term epilepsy treatment."
        }, 
        "brief_title": "Evaluate Retention Rate of Topiramate, Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Epilepsy", 
        "condition_browse": {
            "mesh_term": "Epilepsy"
        }, 
        "detailed_description": {
            "textblock": "Primary objective The Objective of this study is to compare 2-year retention rate of\n      topiramate, levetiracetam and oxcarbazepine in a long term epilepsy treatment.\n\n      Secondary objective The main secondary objective of this study is to evaluate confounding\n      factors associated with retention rate of topiramate compared with other anticonvulsants.\n\n        1. Baseline characteristics\n\n             -  Seizure Type\n\n             -  Gender\n\n             -  Age of onset\n\n        2. Treatment regimen\n\n             -  Number of concomitant medication\n\n             -  Type of drug combination\n\n             -  Final target dose\n\n             -  Titration speed\n\n      Other secondary objectives\n\n      The other secondary objectives of this study are to compare followings by each medication:\n\n        -  Rate of seizure reduction (\u226575%, \u226550%)\n\n        -  Rate of seizure freedom"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who began their treatment with topiramate, levetiracetam or oxcarbazepine as\n             mono or add-on therapy with conventional drugs.\n\n          -  Subjects who are with partial or generalized epilepsy\n\n        Exclusion Criteria:\n\n          -  Subjects who administered combination therapy in topiramate, levetiracetam or\n             oxcarbazepine\n\n          -  Subjects who have past experience of surgery for epilepsy treatment\n\n          -  Subjects who were not followed up for at least 1 year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "95 Years", 
            "minimum_age": "15 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Subjects who newly visited to epilepsy center in a tertiary hospital during January 1st\n        2006 to December 31st of 2010"
            }
        }, 
        "enrollment": {
            "#text": "2500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02098941", 
            "org_study_id": "0620133760"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Etiracetam", 
                "Oxcarbazepine", 
                "Topiramate", 
                "Carbamazepine", 
                "Piracetam"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "topiramate", 
            "oxcarbazepine", 
            "levetiracetam", 
            "retention rate"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "contact": {
                "email": "sangkun2923@gmail.com", 
                "last_name": "Sang kun Lee, MD,PhD"
            }, 
            "contact_backup": {
                "email": "limitsum@gmail.com", 
                "last_name": "Jung-won Shin, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "investigator": {
                "last_name": "Sang kun Lee, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "3", 
        "official_title": "A Retrospective Study to Evaluate Retention Rate of Topiramate With That of Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment", 
        "other_outcome": {
            "measure": "main reasons of drug discontinuation", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "overall_contact": {
            "email": "sangkun2923@gmail.com", 
            "last_name": "Sang kun Lee, MD, PhD"
        }, 
        "overall_contact_backup": {
            "email": "limitsum@gmail.com", 
            "last_name": "Jung-won Shin, MD"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Sang Kun Lee, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Overall retention rates of three treatment groups at two years will be presented in patient number (% of continuation or discontinuation).", 
            "measure": "Retention rate of topiramate, levetiracetam and oxcarbazepine during 24 months of treatment", 
            "safety_issue": "No", 
            "time_frame": "24months"
        }, 
        "reference": [
            {
                "PMID": "20633037", 
                "citation": "Ramsay E, Faught E, Krumholz A, Naritoku D, Privitera M, Schwarzman L, Mao L, Wiegand F, Hulihan J; CAPSS-272 Study Group. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia. 2010 Oct;51(10):1970-7."
            }, 
            {
                "PMID": "18616622", 
                "citation": "Peltola J, Peltola M, Auvinen A, Raitanen J, Fallah M, Ker\u00e4nen T. Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study. Acta Neurol Scand. 2009 Jan;119(1):55-60. doi: 10.1111/j.1600-0404.2008.01062.x. Epub 2008 Jun 24."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02098941"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Sang Kun Lee", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "-Confounding factors associated with retention rate\n: Seizure Type, gender, age, treatment regimen, number of concomitant medication, type of drug combination, final target dose, titration speed", 
                "measure": "Evaluate the confounding factors affecting the retention rate", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Evaluate the response rate through seizure reduction (\u226575%, \u226550%) in 2-year treatment with each antiepileptic drugs (topiramate, levetiracetam, oxcarbazepine)", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Korea, Ltd., Korea", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}